# reload+after+2024-01-20 14:43:53.518814
address1§Kungsbron 1, D5
city§Stockholm
zip§111 22
country§Sweden
phone§46 84 11 30 05
website§https://www.calliditas.se
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
fullTimeEmployees§174
companyOfficers§[{'maxAge': 1, 'name': 'Ms. Renee  Aguiar-Lucander', 'age': 61, 'title': 'Chief Executive Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 8991000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Fredrik  Johansson', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Johan  Haggblad Ph.D.', 'age': 65, 'title': 'Chief Scientific Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 1661000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brian  Gorman', 'title': 'Group General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sandra  Frithiof', 'age': 48, 'title': 'Head of Human Resources', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ann-Kristin  Myde BSc', 'age': 68, 'title': 'Head of Clinical Development & VP of Project Management', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andrew B. Udell B.Sc., M.B.A.', 'age': 53, 'title': 'President of North America Commercial', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Krassimir  Mitchev', 'age': 64, 'title': 'Head of Medical Affairs', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard S. Philipson M.D.', 'age': 59, 'title': 'Chief Medical Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Teona  Johnson', 'title': 'Head of US Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.333
priceToSalesTrailing12Months§0.5380052
currency§USD
dateShortInterest§1702598400
forwardEps§5.46
exchange§NMS
quoteType§EQUITY
shortName§Calliditas Therapeutics AB
longName§Calliditas Therapeutics AB (publ)
firstTradeDateEpochUtc§1591363800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d7b9e28b-d147-3ca9-9029-b131dd8e88fd
gmtOffSetMilliseconds§-18000000
targetHighPrice§55.0
targetLowPrice§17.0
targetMeanPrice§40.67
targetMedianPrice§47.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§2.661
grossMargins§0.96112
ebitdaMargins§-0.30069
trailingPegRatio§None
